These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 10987867)

  • 21. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
    Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
    J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.
    Nikolaou V; Kang X; Stratigos A; Gogas H; Latorre MC; Gabree M; Plaka M; Njauw CN; Kypreou K; Mirmigi I; Stefanaki I; Tsao H
    Br J Dermatol; 2011 Dec; 165(6):1219-22. PubMed ID: 21801156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
    Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
    Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours.
    Marian C; Scope A; Laud K; Friedman E; Pavlotsky F; Yakobson E; Bressac-de Paillerets B; Azizi E
    Br J Cancer; 2005 Jun; 92(12):2278-85. PubMed ID: 15928671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
    Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
    Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
    J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
    Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
    Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
    Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
    Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
    Cebulla CM; Binkley EM; Pilarski R; Massengill JB; Rai K; Liebner DA; Marino MJ; Singh AD; Abdel-Rahman MH
    Ophthalmic Genet; 2015 Jun; 36(2):126-31. PubMed ID: 25687217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rarity of CDK4 germline mutations in familial melanoma.
    Goldstein AM; Chidambaram A; Halpern A; Holly EA; Guerry IV D; Sagebiel R; Elder DE; Tucker MA
    Melanoma Res; 2002 Feb; 12(1):51-5. PubMed ID: 11828258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
    Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
    Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.